Steven Cohen Scholar Rock Holding Corp Transaction History

Point72 Asset Management, L.P.

$39.3 Billion
Q1 2024

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Scholar Rock Holding Corp stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 242,156 shares of SRRK stock, worth $1.85 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

242,156

Previous 1,131,668 78.6%

Holding current value

$1.85 Million

Previous $21.3 Million 79.79%

% of portfolio

0.01%

Previous 0.05%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$13.2 - $17.76 $11.7 Million - $15.8 Million	-889,512 Reduced 78.6%	242,156 $4.3 Million
Q4 2023 Feb 14, 2024	BUY	$6.52 - $20.32 $7.38 Million - $23 Million	1,131,668 New	1,131,668 $21.3 Million
Q1 2023 May 15, 2023	BUY	$7.36 - $12.72 $113,660 - $196,434	15,443 New	15,443 $123,000
Q2 2020 Aug 14, 2020	SELL	$10.37 - $20.64 $3.56 Million - $7.09 Million	-343,333 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$9.63 - $17.14 $2.57 Million - $4.57 Million	266,869 Added 349.01%	343,333 $4.16 Million

Q4 2019 Feb 14, 2020	BUY	$7.2 - $13.2 $550,540 - $1.01 Million	76,464 New	76,464 $1.01 Million
Q2 2019 Aug 14, 2019	SELL	$14.61 - $22.45 $2.92 Million - $4.49 Million	-200,000 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$14.24 - $22.28 $2.85 Million - $4.46 Million	200,000 New	200,000 $3.76 Million
Q3 2018 Nov 14, 2018	SELL	$13.39 - $26.25 $129,883 - $254,625	-9,700 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$15.0 - $25.6 $145,500 - $248,320	9,700 New	9,700 $151,000

Others Institutions Holding SRRK

# of Institutions

165

Shares Held

73.6M

Call Options Held

501K

Put Options Held

26.3K

View Full List

About Scholar Rock Holding Corp

Ticker SRRK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,640,600
Market Cap $394M
Description
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clini...

More about SRRK

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account